ATLANTA, April 17, 2025 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO). The lawsuit alleges that the Company’s Registration Statement contained materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO.
If you bought shares of Zenas BioPharma pursuant and/or traceable to the Registration Statement and related prospectus issued in connection with its September 2024 IPO, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/zenas-biopharma/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is June 16, 2025.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
